| Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus G Curigliano, S Banerjee, A Cervantes, MC Garassino, P Garrido, ... Annals of Oncology 31 (10), 1320-1335, 2020 | 278 | 2020 |
| Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer A Addeo, PK Shah, N Bordry, RD Hudson, B Albracht, M Di Marco, ... Cancer cell 39 (8), 1091-1098. e2, 2021 | 217 | 2021 |
| ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer A Passaro, A Addeo, C Von Garnier, F Blackhall, D Planchard, E Felip, ... ESMO open 5, e000820, 2020 | 117 | 2020 |
| Cancer and COVID-19: Unmasking their ties A Addeo, A Friedlaender Cancer treatment reviews 88, 102041, 2020 | 113 | 2020 |
| How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere G Banna, A Curioni-Fontecedro, A Friedlaender, A Addeo ESMO open 4, e000765, 2019 | 113 | 2019 |
| TMB or not TMB as a biomarker: That is the question A Addeo, A Friedlaender, GL Banna, GJ Weiss Critical Reviews in Oncology/Hematology 163, 103374, 2021 | 99 | 2021 |
| EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment A Friedlaender, V Subbiah, A Russo, GL Banna, U Malapelle, C Rolfo, ... Nature reviews Clinical oncology 19 (1), 51-69, 2022 | 98 | 2022 |
| Tumor mutation burden—from hopes to doubts A Addeo, GL Banna, GJ Weiss JAMA oncology 5 (7), 934-935, 2019 | 98 | 2019 |
| Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and … A Addeo, GL Banna, G Metro, M Di Maio Frontiers in oncology 9, 264, 2019 | 91 | 2019 |
| KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures A Friedlaender, A Drilon, GJ Weiss, GL Banna, A Addeo Cancer treatment reviews 85, 101978, 2020 | 86 | 2020 |
| Oncogenic driver mutations in non-small cell lung cancer: Past, present and future M Chevallier, M Borgeaud, A Addeo, A Friedlaender World Journal of Clinical Oncology 12 (4), 217, 2021 | 85 | 2021 |
| New emerging targets in cancer immunotherapy: the role of TIM3 A Friedlaender, A Addeo, G Banna ESMO open 4, e000497, 2019 | 83 | 2019 |
| Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab … A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ... Journal for immunotherapy of cancer 9 (4), 2021 | 81 | 2021 |
| COVID-19 and lung cancer: risks, mechanisms and treatment interactions A Addeo, M Obeid, A Friedlaender Journal for immunotherapy of cancer 8 (1), 2020 | 67 | 2020 |
| Next generation sequencing and genetic alterations in squamous cell lung carcinoma: where are we today? A Friedlaender, G Banna, U Malapelle, P Pisapia, A Addeo Frontiers in oncology 9, 166, 2019 | 66 | 2019 |
| The FDA approval of pembrolizumab for patients with TMB> 10 mut/Mb: was it a wise decision? No V Prasad, A Addeo Annals of Oncology 31 (9), 1112-1114, 2020 | 65 | 2020 |
| Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50% A Cortellini, M Tiseo, GL Banna, F Cappuzzo, JGJV Aerts, F Barbieri, ... Cancer Immunology, Immunotherapy 69, 2209-2221, 2020 | 64 | 2020 |
| Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression≥ 50%: a multicenter study with external validation A Cortellini, B Ricciuti, M Tiseo, E Bria, GL Banna, JGJV Aerts, F Barbieri, ... Journal for immunotherapy of cancer 8 (2), 2020 | 63 | 2020 |
| Immunotherapy in non-small cell lung cancer harbouring driver mutations A Addeo, A Passaro, U Malapelle, GL Banna, V Subbiah, A Friedlaender Cancer treatment reviews 96, 2021 | 59 | 2021 |
| Targeted therapies in early stage NSCLC: hype or hope? A Friedlaender, A Addeo, A Russo, V Gregorc, D Cortinovis, CD Rolfo International journal of molecular sciences 21 (17), 6329, 2020 | 56 | 2020 |
Alex FriedlaenderGenevaVerified email at hcuge.ch
